Want to see FR:IVA full AI Analyst Report?
IVA Stock Chart & Stats
€3.82
€0.17(4.45%)
At close: 4:00 PM EDT
€3.82
€0.17(4.45%)
Day’s Range― - ―
52-Week Range€2.88 - €6.20
Previous CloseN/A
Volume253.81K
Average Volume (3M)416.07K
Market Cap
€934.31M
Enterprise Value€722.43
Total Cash (Recent Filing)€230.87M
Total Debt (Recent Filing)€59.86M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Sep 25, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding236,280,200
10 Day Avg. Volume620,713
30 Day Avg. Volume416,066
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-25.87
Price to Sales (P/S)164.59
P/FCF Ratio-7.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.57Price Target Upside124.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.66
Revenue Forecast (FY)€6.03M
Bulls Say, Bears Say
Bulls Say
Phase III ExecutionCompletion of a large, well-powered global Phase III trial materially reduces execution risk and creates a defined regulatory inflection point. Strong operational controls and low dropout rates support the reliability of the upcoming efficacy assessment.
Cash RunwayThe substantial cash position gives Inventiva resources to complete NATiV3 and operate through the expected readout period without relying immediately on another financing. This improves development continuity and preserves flexibility while the lead asset approaches a major milestone.
Lanifibranor Differentiation And Market OpportunityPrior efficacy signals, Breakthrough Therapy and Fast Track designations, and a large underdiagnosed MASH population provide a credible foundation for potential commercial relevance. Metabolic benefits could also support positioning in patients with broader cardiometabolic needs.
Bears Say
No Recurring Product Revenue And Sustained LossesThe company has no approved product to generate recurring sales, leaving near-term economics dependent on financing, partnerships, or milestone receipts. Sharp revenue deterioration and deep losses indicate that commercial self-funding remains distant and execution depends on clinical success.
Negative Equity And Persistent Cash BurnNegative equity reflects accumulated losses overwhelming the capital base and limits balance-sheet flexibility. Ongoing real cash consumption means the company will likely require additional capital or partnering proceeds beyond the current runway if development and commercialization efforts continue.
Clinical, Safety And Financing DependenceLanifibranor remains exposed to a delayed and uncertain Phase III outcome, with future funding partly contingent on milestones and investor participation. PPAR-related weight gain and fluid retention may constrain labeling or adoption, especially in a competitive MASH market.
Inventiva News
IVA FAQ
What was Inventiva SA’s price range in the past 12 months?
Inventiva SA lowest stock price was €2.88 and its highest was €6.20 in the past 12 months.
What is Inventiva SA’s market cap?
Inventiva SA’s market cap is €934.31M.
When is Inventiva SA’s upcoming earnings report date?
Inventiva SA’s upcoming earnings report date is Sep 25, 2026 which is in 30 days.
How were Inventiva SA’s earnings last quarter?
Inventiva SA released its earnings results on Mar 30, 2026. The company reported -€0.926 earnings per share for the quarter, missing the consensus estimate of -€0.237 by -€0.689.
Is Inventiva SA overvalued?
According to Wall Street analysts Inventiva SA’s price is currently Undervalued.
Does Inventiva SA pay dividends?
Inventiva SA does not currently pay dividends.
What is Inventiva SA’s EPS estimate?
Inventiva SA’s EPS estimate is -0.33.
How many shares outstanding does Inventiva SA have?
Inventiva SA has 236,280,200 shares outstanding.
What happened to Inventiva SA’s price movement after its last earnings report?
Inventiva SA reported an EPS of -€0.926 in its last earnings report, missing expectations of -€0.237. Following the earnings report the stock price went down -1.042%.
Which hedge fund is a major shareholder of Inventiva SA?
Currently, no hedge funds are holding shares in FR:IVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Inventiva SA
Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
IVA Stock 12 Month Forecast
Average Price Target
€8.57
▲(124.32% Upside)